Cullinan Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cullinan Therapeutics (CGEM).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$30Upside to Avg. PT+94.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$35
Sep 25, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$30→$35
Sep 25, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Sep 14, 2026	BTIG	Julian Harrison	PT Raise	Buy	$39→$40
Aug 17, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$30
Aug 13, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$39→$42
Jul 29, 2026	BTIG	Julian Harrison	PT Raise	Buy	$38→$39
Jun 11, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$37
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$30
May 19, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
May 8, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$36→$37
May 4, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
Apr 28, 2026	BTIG	Julian Harrison	Maintained	Buy	$38
Apr 28, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$27→$30
Mar 11, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$34→$36
Feb 17, 2026	Citigroup	Samantha Semenkow	Initiate	Buy	$33
Feb 2, 2026	Guggenheim	Brad Canino	Initiate	Buy	$30
Jan 8, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$26→$27
Dec 9, 2025	Wedbush	Robert Driscoll	PT Raise	Outperform	$25→$34
Nov 24, 2025	BTIG	Julian Harrison	PT Raise	Buy	$32→$38

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.

Benzinga Newsdesk

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Vandana Singh

Cullinan Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Cullinan Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

PRO
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

PRO
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

People Also Watch

People Also Watch

Cullinan Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Cullinan Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

PROBTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

PROBTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

PROHC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35

PRO
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target

PRO
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40

PRO
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target